Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients: A systematic review and meta-analysis

Journal of Chinese Integrative Medicine

Volumn 10, Issue 12, 2012, Pages 1341-1362

  Li, Xiao Qian ^a   Ling, Chang Quan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chinese herbal medicine; Embolization; Liver neoplasms; Meta analysis; Randomized controlled trials; Side effects; Therapeutic

Indexed keywords

ABDOMINAL PAIN; ANOREXIA; BONE MARROW SUPPRESSION; CHEMOEMBOLIZATION; CHINESE MEDICINE; FEVER; HERBAL MEDICINE; HUMAN; IMMUNOLOGICAL PARAMETERS; LIFE EXPECTANCY; LIVER CANCER; LIVER FUNCTION; LIVER PAIN; META ANALYSIS; NAUSEA AND VOMITING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR VOLUME;

CHEMOEMBOLIZATION, THERAPEUTIC; DRUGS, CHINESE HERBAL; HUMANS; LIVER NEOPLASMS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872023726     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20121204     Document Type: Review

References (99)

1. Abou-Alfa GK, DeMatteo RP. 100 questions &. answers about liver cancer. 2nd ed. Sudbury: Jones and Bartlett Publishers. 2008.
2. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer. 2001; 94(2): 290-296.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61 (2): 69-90.
4. Bosch FX, Ribes J, Diazm, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl1): S5-S16.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59 (4): 225-249.
6. Hayat MA. Introduction. In: Hayat MA. Methods of cancer diagnosis, therapy, and prognosis: liver cancer. Dordrecht: Springer. 2009: xvii.
7. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009; 286(1): 9-14.
8. Kjaergard LL, Villumsen J, Gluud C. Reported meth-odologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001; 135(11): 982-989.
9. Blum HE. Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005; 19(1): 129-145.
10. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002; 35(3): 519-524.
11. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005; 234(3): 961-967.
12. Yamada R, Nakatsuka H, Nakamura K. Transcatheter arterial embolization therapy in unresectable hepatomas: experience in 15 cases. Acta Hepatologica Jpn. 1979; 20(6): 595-603. Japanese with abstract in English.
13. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemo-embolization improves survival. Hepatology. 2003; 37 (2): 429-442.
14. Xia J, Ren Z, Ye S, Sharma D, Lin Z, Gan Y, Chen Y, Ge N, Ma Z, Wu Z, Fan J, Qin L, Zhou X, Tang Z, Yang B. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol. 2006; 59(3): 407-412.
15. Chiu J, Yau T, Epstein RJ. Complications of traditional Chinese/herbal medicines (TCM) - a guide for perplexed oncologists and other cancer caregivers. Support Care Cancer. 2009; 17(3): 231-240.
16. Wu MC. Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems. J Chin Integr Med. 2003; 1 (3): 163-164. Chinese. Chinese Source- 2003; 1(3): 163-164
17. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med. 2007; 13(8): 353-361.
18. Yuan R, Lin Y. Traditional Chinese medicine: an approach to scientific proof and clinical validation. Pharmacol Ther. 2000; 86(2): 191-198.
19. Tierra M. Treating cancer with herbs: an integrative approach. Twin Lakes: Lotus Press. 2003.
20. Zhu YP, Woerdenbag HJ. Traditional Chinese herbal medicine. Pharm World Sci. 1995; 17(4): 103-112.
21. Ergil KV, Kramer EJ, Ng AT. Chinese herbal medicine. West J Med. 2002; 176(4): 275-279.
22. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials. 1998; 19(2): 159-166.
23. Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol. 2007; 18(4): 768-774.
24. Wu T, Munro AJ, Liu GJ. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005; (1): CD004540.
25. Rui D, Xiaoyan C, Taixiang W, Guanjian L. Elemene for the treatment of lung cancer. Cochrane Database Syst Rev. 2007; (4): CD006054.
26. Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007; (2): CD004921.
27. Gan T, Wu Z, Tian L, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev. 2011; (2): CD005096.
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11): 1539-1558.
29. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). Cochrane Database Syst Rev. 2010; (10): LIVER.
30. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995; 273(5): 408-412.
31. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998; 352 (9128): 609-613.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997; 315(7109): 629-634.
33. Wood L, Egger M, Gluud LL, Schulz KF, Jiini P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne J A. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008; 336 (7644): 601-605.
34. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated September 2009] edition. The Cochrane Collaboration. 2009.
35. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-560.
36. Bai GD, Lian ZP, Huang DP, Hou EC, Lu YX, Lin MY. Zini Yigan Formula combined with Western medicine in the treatment of 30 cases of middle- or late- stage hepatoma. Shaanxi Zhong Yi. 2008; 29(1): 16-19. Chinese. Chinese Source. 2008; 29(1): 16-19.
37. Bai GD, Lian ZP, Huang DP, Hou EC, Lu YX, Lin MY, Guan Y. Clinical study on integrated traditional Chinese and Western medicine in the treatment of 26 cases of middle- or late- stage hepatoma. Jiangsu Zhong Yi Yao. 2008; 40(8): 27-29. Chinese. Chinee Source 2008; 40(8): 27-29.
38. Chen WS, Huang LY, Zhou XJ, Jin C, Li ZB, Li WD, Ma L. Clinical observation of granisetron combined with Huolisu Oral Liquid on the digestive tract reactions in liver cancer patients after intervention therapy. Ying Xiang Zhen Duan Yu Jie Ru Fang She Xue. 2003; 12 (2): 112-114. Chinese. Chinese Source 2003; 12(2): 112-114.
39. Dong HJ, Hu JN. Digestive tract reactions to acupoint application of Chinese herbal medicine after treatment with transarterial chemoembolization. Hu Li Xue Za Zhi. 2002; 17(9): 670-671. Chinese. Chinese Source. 2002; 17(9): 670-671.
40. Feng YL, Ling CQ, Li B, Chen Z, Yu CQ. Clinical study on integrative medicine for preventing and treating post-transcatheter arterial chemoembolization. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005; 25 (6): 534-536. Chinese with abstract in English. Chinese Source 2005; 25(6): 534-536.
41. Feng MH, Pang J. Short-term effects of Chinese herbal medicine in the treatment of post-TACE syndrome. Changchun Zhong Yi Yao Da Xue Xue Bao. 2010; 26(4): 499-500. Chinese. Chinese Source. 2010; 26(4): 499-500.
42. Guo TS, Huang FX, Cao XL. Clinical observation on Huaier Granule combined with intervention therapy in the treatment of primary liver cancer. Shi Yong Yi Xue ZaZhi. 2005; 21(16): 1846-1847. Chinese. Chinese Source. 2005; 21(16): 1846-1847.
43. Hou EC, Lu YX. Prmiary hepatocarcinoma treated by traditional Chinese medicine combined with transcatheter arterial chemoembolization. Zhongguo Zhong Xi Yi Jie HeZaZhi. 2009; 29(3): 225-227. Chinese with abstract in English. Chinese Source. 2009; 29(3): 225-227.
44. Huang L, Huang T, Zhang XL. Integrated traditional Chinese and Western medicine in treating 18 cases of post-TACE syndrome. Shandong Zhong Yi Za Zhi. 2010; 29(7): 471-472. Chinese. Chinese Source. 2010; 29 (7): 471-472.
45. Jia CH, Wang WY, Kang Y. Clinical studies on combination therapy of Jinlong Capsule and transarterial chemoembolization in treatment of primary hepatic carcinoma. Zhonghua Zhong Liu Fang Zhi Za Zhi. 2008; 15(18): 1416-1418. Chinese with abstract in English. 2008; 15(18): 1416-1418.
46. Lao YQ. Clinical study on effect of Matrine Injection to protect the liver function for patients with primary hepatic carcinoma after trans-artery chemo-embolization (TAE). Zhong Yao Cai. 2005; 28(7): 637-638. Chinese with abstract in English. Chinese Source 2005; 28(7): 637-638.
47. Li M. Impact of Sianpi Huoxue Formula on quality of life in patients with liver cancer after transarterial chemoembolization. Zhong Wai Jian Kang Wen Zhai. 2007; 4(3): 62-64. Chinese. Chinese Source. 2007; 4(3): 62-64.
48. Li M. Impact of Jianpi Huoxue Formula combined with transarterial chemoembolization on quality of life in patients with liver cancer. Shaanxi Zhong Yi. 2011; 32(7): 854-856. Chinese. Chinese Source. 2011; 32(7): 854-856.
49. Li Q, Sun BM, Peng YH, Fan ZZ, Sun J. Clinical study on the treatment of primary liver cancer by cinobufotain combined with transcatheter arterial chemoembolization. Shanghai Zhong Yi Yao Da Xue Xue Bao. 2008; 22(2): 32-34. Chinese with abstract in English. Chinese Source 2008; 22(2): 32-34.
50. Li RL. Clinical observation on transarterial chemoembolization combined with Chinese herbal medicine in treating stage HI liver cancer. Zhongguo Min Kang Yi Xue. 2009; (1): 32-34. Chinese. Chinese Source. 2009; (1): 32-34.
51. Li YH, Liang H, Zhang CH. Clinical observation on the effect of Chinese herbal medicine combined with transarterial chemoembolization in the treatment of primary liver cancer. Nanjing Yi Ke Da Xue Xue Bao Zi Ran Ke Xue Ban. 2011; 31(5): 742-745. Chinese. Chinese Source. 2011; 31(5): 742-745.
52. Lin J. Clinical observation on the effect of Fuzheng Jiedu Formula combined with transarterial chemoembolization in the treatment of primary liver cancer. Hubei Zhong YiZaZhi. 2008; 30(2): 30-31. Chinese. Chinese Source. 2008; 30(2): 30-31.
53. Liu CL, Cai YC, Huang ZY, Gu YL, Liu RP. Clinical study on effect of Chinese herbal medicine on liver damage caused by hepatic artery chemoembolization. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1999; 19 (5): 276-278. Chinese with abstract in English. Chinese Source 1999; 19(5): 276-278.
54. Liu HQ, Chen SX, Li Y, Huang RW. Clinical observation of Kang'ai injection with TACE in 34 patients with hepatocellular carcinoma (HC). Hainan Yi Xue. 2007; 18(8): 19-20. Chinese with abstract in English. Chinese Source 2007; 18(8): 19-20.
55. Liu JR. Effect of Chinese herbal medicine in reducing the toxic and side effects of intervention therapy for liver cancer. Beijing: Beijing University of Chinese Medicine. 2010. Chinese with abstract in English. Chinese Source. 2010.
56. Liu Y. Effect of Huaji Jianpi Formula on immune function after hepatic artery chemoembolization in patients with primary liver cancer. Fuzhou: Fujian University of Traditional Chinese Medicine. 2009. Chinese with abstract in English. Chinese Source. 2009.
57. Lu Y. Clinical study on Jianpi Jiedu Formula in treating primary liver cancer and its mechanisms. Nanjing: Nanjing University of Chinese Medicine. 2011. Chinese with abstract in English. Chinese Source. 2011.
58. Luo HY, Wu WY, Lu JR, Xu K, Liu WS, Zhu DY, Li LN. Effects of Qingkailing Injection on post-transcatheter arterial chemoembolization syndrome in patients with primary liver cancer. Guangzhou Zhong Yi Yao Da Xue Xue Bao. 2001; 18(2): 130-133. Chinese with abstract in English. Chinese Source. 2001; 18(2): 130-133.
59. Lu XC, Liu JL, Zhang QX, Guo J, Meng AG, Wang YT, Zhang ZH, Chen SQ. Clinical study on treatment of primary hepatocarcinoma by intensive compositive integrated traditional Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Ji Jiu Za Zhi. 2001; 8 (5): 306-308. Chinese with abstract in English. Chinese Source. 2001; 8(5): 306-308.
60. Mao CH, Yuan YF. Clinical observation on the effect of Chaishaoliujunzi Decoction for prevention of side effects caused by interventional therapy in primary hepatic carcinoma. Zhong Yi Yao Dao Bao. 2007; 13(9): 2526. Chinese. Chinese Source. 2007; 13(9): 25-26.
61. Meng SX. Observation on the effect of Yigan Decoction in reducing the side effects of transarterial chemoembolization. Zhongguo Zhong Yi Ji Zheng. 2009; 18(2): 195-196. Chinese. Chinese Source. 2009; 18(2): 195-196.
62. Ouyang QZ. Effects of invigorating the spleen combined with pressing ear acupoints in the treatment of post-transarterial chemoembolization syndrome. Guangzhou: Guangzhou University of Chinese Medicine. 2011. Chinese with abstract in English. Chinese Source. 2011.
63. Qian J, Huang FF. Effect of the treatment of 43 primary hepatocarcinoma patients with the combination of Anti-hepatocarcinoma Mixture with arteria hepatica perfusion chemotherapy and embolotherapy. Yunnan Zhong Yi Zhong Yao Za Zhi. 2007; 28(8): 6-7. Chinese. 2007; 28(8): 6-7.
64. Song XR, Zhao QD, Zhang M. Observation on the effect of Chinese herbal medicine combined with transarterial chemoembolization in the treatment of liver cancer. Zhongguo Lin Chuang Yi Sheng Za Zhi. 2007; 35(6): 38-40. Chinese. Chinese Source. 2007; 35(6): 38-40.
65. Sun XP, Zhang GY, Xu HM, Xing JX. The clinical study of interventional therapy combining with Jianpi Shugan decoction for treatment of primary hepatic carcinoma with spleen hyperfunction. Zhongguo Zhong Xi Yi Jie He Ying Xiang Xue Za Zhi. 2007; 5(2): 84-86. Chinese with abstract in English. Chinese Source. 2007; 5(2): 84-86.
66. Wang LL, Zhang XB, Wang SL. Clinical observation on Chinese herbal medicine in preventing and treating post-TACE syndrome. Zhongguo Zhong Yi Ji Zheng. 2006; 15(10): 1088-1089. Chinese. Chinese Source. 2006; isao): 1088-1089.
67. Wang WH, Zhou RY, Yan ZP, Lin JH, Ye ZB, Wu DM, Wu LY, Wu HL. Regulatory efect of Bushen Jianpi Recipe on cellular immunity of patients with primary liver cancer after intervention therapy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008; 28(7): 583-587. Chinese with abstract in English. Chinese Source, 2008; 28(7): 583-587.
68. Wang YZ, Yao SK, Gao LM, Li ZG, Gu TS. Clinical study on the effect of Qinggan Huayu Oral Liquid on the immune function of liver cancer patients after intervention therapy. Zhongguo Lao Nian Xue Za Zhi. 2008; 28(8): 770-772. Chinese. Chinese Source. 2008; 28(8): 770-772.
69. Wen LH, Zeng GB, Wen XL. Clinical observation on the method of strengthening the body and eliminating evil in treating 50 cases of post-TACE syndrome. Xin Zhong Yi. 2006; 38(9): 24-25. Chinese. Chinese Source 2006; 38(9): 2425.
70. Wu GL, Zhang L, Li TY, Chen J, Yu GY, Li JP. Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression. Chin J Integr Med. 2010; 16(2): 109-113.
71. Xiong JL. Clinical observation on chemoembolization combined with Xiaoyao Powder in treating 24 cases of primary liver cancer. Zhong Yi Yao Dao Bao. 2011; 17 (2): 18-20. Chinese. Chinese Source 2011; 17(2): 18-20.
72. Xu WJ, Sun XF, Zhou XZ, Ma WF, Huang QG, Zhan BL, Zhou DQ. Clinical analysis on Kang'ai Fang combined with TACE for treatment of HCC. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2011; 21 (2): 74-76. Chinese with abstract in English. Chinese Source. 2011; 21 (2): 74-76.
73. Yang W, Yang HS, He XJ, Li XH, Qian Y. Clinical observation of 65 cases with hepatocellular carcinoma treated by Huqisan and transeatheter arterial chemoembolization. Shou Du Yi Ke Da Xue Xue Bao. 2009; 30 (1): 37-39. Chinese with abstract in English. Chinese Source 2009; 30(1): 37-39.
74. Yang XW, Ma B. Study on the liver-protective effect of Chinese herbal medicine after transarterial chemoembolization. Zhong Yi Yao Xue Kan. 2003; 21(7): 1119-1120. Chinese. Chinese Source 2003; 21(7): 1119-1120.
75. Yu ML, Kang XH. Clinical study on Compound Matrine Injection combined with transarterial chemoembolization in the treatment of primary liver cancer. Zhongguo Yi Yao Zhi Nan. 2010; 8(7): 123-125. Chinese. Chinese Source. 2010; 8 (7): 123-125.
76. Yu X. Clinical study on the method of resolving blood stasis and clearing toxin combined with interventional therapy in the treatment of middle- or late- stage primary liver cancer. Beijing: Beijing University of Chinese Medicine. 2007. Chinese with abstract in English. Chinese Source. 2007.
77. Zhai RQ, Zhai HY. Clinical observation of Chinese medicine combined with transcatheter arterial chemoembolization in treating 32 cases of advanced primary hepatic carcinoma. Shanghai Zhong Yi Yao Za Zhi. 2010; 44 (11): 48-51. Chinese. Chinese Source 2010; 44(11): 48-51.
78. Zhang HT, Fang CT, Huang ZY, Wang G. Chinese herbal medicine combined with intervention therapy in the treatment of 31 cases of primary liver cancer. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2008; 18(3): 178-180. Chinese.? Chinese Source. 2008; 18 (3): 178-180.
79. Zhang SY, Gu CH, Gao XD, Wu YL. A randomly, double-blinded, and multicentre study of chemotherapy assisted with Yangzhengxiaoji capsule on treating primary hepatic carcinoma. Yi Nan Bing Za Zhi. 2009; 8(8): 461-464. Chinese with abstract in English. Chinese Source. 2009; 8(8): 461-464.
80. Zhang XY. Clinical observation on integrated traditional Chinese and Western medicine in the treatment of 49 cases of primary liver cancer. Dang Dai Yi Xue. 2011; 17 (6): 161-164. Chinese. 2011; 17(6): 161-164.
81. Zhao J. Rougan Jianpi Formula in the prevention and treatment of liver injury after transcatheter arterial chemoembolization. Shandong Zhong Yi Yao Da Xue Xue Bao. 2009; 33(1): 35-36. Chinese. Chinese Source 2009; 33(1): 35-36.
82. Zheng L, Feng JP, Li M, Fang J, Wang YP. Clinical observation on Chinese herbal medicine combined with transcatheter arterial chemoembolization in the treatment of middle- or late- stage liver cancer. Hubei Zhong Yi Za Zhi. 2010; 32(7): 12-14. Chinese. Chinese Source. 2010; 32(7): 12-14.
83. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vase Interv Radiol. 2001; 12(3): 321-326.
84. Wigmore SJ, Redhead DN, Thomson BN, Currie EJ, Parks RW, Madhavan KK, Garden OJ. Postchemoem-bolisation syndrome - tumour necrosis or hepatocyte injury? Br J Cancer. 2003; 89(8): 1423-1427.
85. Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, Cicorelli A, Tumino E, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study. Eur J Radiol. 2012; 81(6): 1173-1178.
86. Zwahlen M, Renehan A, Egger M. Meta-analysis in medical research: Potentials and limitations. Urol Oncol. 2008; 26(3): 320-329.
87. Huwiler-Miintener K, Jiini P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA. 2002; 287(21): 2801-2804.
88. Li XQ, Tao KM, Zhou QH, Ling CQ. Scientific publications from Mainland China, Taiwan, and Hong Kong in integrative and complementary medicine journals: a ten-year literature survey. Am J Chin Med. 2011; 39(4): 639-649.
89. Li XQ, Tao KM, Zhou QH, Moher D, Chen HY, Wang FZ, Ling CQ. Endorsement of the CONSORT Statement by high-impact medical journals in China: a survey of instructions for authors and published papers. PLoS One. 2012; 7(2): e30683.
90. Liu JP. Methodological quality assessment of clinical trials in traditional Chinese medicine: the principles of evidence-based medicine. J Chin Integr Med. 2006; 4 (1): 1-6. Chinese with abstract in English. Chinese Source. 2006; 4(1): 1-6.
91. Liu JP, Kjaergard LL, Gluud C. Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. Am J Chin Med. 2002; 30(1): 173-176.
92. Liu JP. Concepts and methods of randomization in clinical trials. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003; 23 (4): 244-246. Chinese. 2003; 23(4): 244-246.
93. Pildal J, Hrobjartsson A, jorgensenKJ, HildenJ, Altman DG, G0tzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007; 36(4): 847-857.
94. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ. 2005; 330(7499): 1057-1058.
95. Jiini P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323(7303): 42-46.
96. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004; 328(7437): 432.
97. Guo XF, Zhu Q, Lai SL. Thinking on surrogate outcomes, intermediary outcomes and their application in TCM clinical efficacy evaluation. Zhongguo Zhong Xi Yi Jie HeZaZhi. 2005; 25(7): 585-590. Chinese with abstract in English. Chinese Source. 2005; 25(7): 585-590.
98. Guo XF, Lai SL, Liang WX. Choice and application of the outcome indexes for clinical effectiveness assessment of traditional Chinese medicine. Guangzhou Zhong Yi Yao Da Xue Xue Bao. 2002; 19(4): 251-255. Chinese with abstract in English. Chinese Source 2002; 19 (4): 251-255.
99. Bian ZX, Moher D, Dagenais S, Li YP, Wu TX, Liu L, Miao JX, Song L, Zhang HM. Improving the quality of randomized controlled trials in Chinese herbal medicine, Part IY: applying a revised CONSORT checklist to measure reporting quality. J Chin Integr Med. 2006; 4 (3): 233-242. English with abstract in Chinese. Chinese Source 2006; 4 (3): 233-242.